Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant degarelix + erdafitinib before radical prostatectomy for high-risk prostate cancer
ACTRN12618001061224Phase 2Terminated
- Sponsor
- Melbourne Health
- Start
- Mar 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of degarelix and erdafitinib in prostate cancer (PCa), sponsored by Melbourne Health. Primary endpoints: Safety and tolerability of degarelix + erdafitinib in the neoadjuvant setting and pT0 response rate. Started Mar 2019; status: terminated.
02
Drugs
degarelixerdafitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12618001061224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001061224.